Actively Recruiting
HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-06-12
380
Participants Needed
14
Research Sites
235 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective is to demonstrate the superiority of arginine-vasopressin (AVP) and hydrocortisone compared with norepinephrine regarding day-30 survival and neurological recovery in post-cardiac arrest patients with hemodynamic failure.
CONDITIONS
Official Title
HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients older than 18 years
- Cardiac arrest (in-hospital or out-of-hospital) with sustained return of spontaneous circulation lasting more than 30 minutes admitted to the ICU
- Post-resuscitation shock with low blood pressure (SAP < 90 mmHg or MAP < 65 mmHg) not responding to fluids, occurring within 24 hours after ROSC and requiring norepinephrine/epinephrine continuous infusion at a dose ≥ 0.2 µg/kg/min for at least 3 hours
- Maximum delay between the start of norepinephrine infusion and randomization is 9 hours
- Informed written consent from the patient or legally authorized close relative
You will not qualify if you...
- Cardiac arrest caused by trauma or neurological conditions
- Shock caused by uncontrolled bleeding
- Known adrenal insufficiency
- Limitation of life-sustaining treatments
- Current treatment with any steroids
- Ongoing extracorporeal circulatory assistance
- Gastrointestinal bleeding within the past 6 weeks
- Pregnant or breastfeeding women
- Participation in another interventional study or within an exclusion period after such a study
- Allergic reaction to arginine-vasopressin or hydrocortisone or their components
- Legal protection status preventing consent (guardianship, curator, incarceration)
- No affiliation with the French health care system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Intensive care unit, CHU Amiens- Picardie
Amiens, France
Actively Recruiting
2
Intensive care unit, CHU Angers
Angers, France
Actively Recruiting
3
Intensive care unit, CHI Robert Ballanger
Aulnay-sous-Bois, France
Actively Recruiting
4
Medical Intensive Care Unit, Ambroise Paré hospital, APHP
Boulogne-Billancourt, France, 92100
Withdrawn
5
Intensive care unit, CH public du Cotentin
Cherbourg, France
Actively Recruiting
6
Intensive care unit, CHU Dijon
Dijon, France
Actively Recruiting
7
Intensive care unit, Hospices civils de Lyon
Lyon, France
Actively Recruiting
8
Intensive care unit, Hôpital Jacques Cartier
Massy, France
Actively Recruiting
9
Intensive care unit, CHU Montpellier
Montpellier, France
Actively Recruiting
10
Intensive care unit, Brabois hospital
Nancy, France
Actively Recruiting
11
Intensive care unit, Hotel Dieu hospital
Nantes, France
Actively Recruiting
12
Intensive care unit, Clinique Ambroise Paré
Neuilly-sur-Seine, France, 92200
Actively Recruiting
13
Intensive care unit, Cochin hospital, APHP
Paris, France, 75014
Actively Recruiting
14
Intensive care unit, André Mignot hospital
Versailles, France
Actively Recruiting
Research Team
G
Guillaume GERI, MD, PhD
CONTACT
A
Alain Cariou, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here